Articles On Neurotech International (ASX:NTI)

Twitter to allow cannabis companies to advertise in US states where it’s legal Elixnol comes out on top with CannaCare Health arbitration awarded in their favour Avecho expands CBD soft-gel capsule trials with the Lambert Initiative   Twi...

Neurotech International (NTI) treats its first patient in its phase one and two paediatric clinical trials The trials are assessing the company’s NTI164 product in children with paediatric autoimmune neuropsychiatric disorders associated...

Neurotech International (NTI) is granted approval to begin phase one and two paediatric clinical trials The company received written approval from the Human Research Ethics Committee (HREC), along with clinical trial notification scheme...

US States who allow recreational cannabis see less codeine demand WA GP wants Snoop Dogg to drop into parliament to chat cannabis reform Neurotech nabs pre-submission meeting with US FDA for CBD drug NTI164   A Cornell University study ha...

Good gravy, what a Monday that was – the Stockhead newsroom’s been busier than Santa’s elves this week, as the ASX is inundated with last-minute, pre-Christmas stock market shenanigans. Maybe staying up to watch the World Cup final wasn’t s...

UBI will have its work published on the front cover of respected publication Neurotech gets green light for Phase II/III trial Sonic Healthcare’s revenue disappoints UBI’s work gets published Universal Biosensors (ASX:UBI) rose 6% this mo...

Neurotech International (NTI) taps investors for $9 million to fund its paediatric clinical trials programInstitutional, professional and sophisticated investors have made binding commitments for a placement comprising 90 million new shares...

Germany looks to legalise recreational cannabis and US and Canadian companies are paying attention  Neurotech reports success with its cannabis-based drug for paediatric autism symptoms  ECS Botanics has sold its Tasmanian business and a...

Neurotech says its NTI164 drug for paediatric autism showed improvements in symptoms Arovella closing Perth R&D facility to focus on invariant Natural Killer T (iNKT) cell platform Argenica reports safety and efficiacy of stroke drug A...

ASX200 is in the green on Wednesday morning New British PM brings yields back to Pre-Liz levels Amazon and Meta to report after the close tonight Local shares are set to open higher again on Wednesday morning after a rather light night of...

Tuesday. The day when the grind of the week is well and truly entrenched, and the weekend is just a wistful speck in the distance, beckoning us forward, inch by dreadful inch, with promises of sleeping late, fishing adventures and absolutel...

The ASX 200 trims gains to end circa 0.3% higher Small caps drop 0.2%, but C29 Metals booms China markets still choppy after political appointments   The big show, if balancing books and picking pre-chosen soundbytes is your thing, begins...

Patrys crosses blood brain barrier in health animals Cynata receives Notice of Acceptance from IP Australia Telix announces collaboration with GE Healthcare Patrys (ASX:PAB) surged 15% this morning after announcing that its full-sized deo...

Neurotech is anticipating results from its extended world first study of a medicinal cannabis product in children which could be a game-changer in autism treatment. Clinical-stage biopharmaceutical company focused predominantly on pediatric...

Cambridge says cannabis smokers are not actually lazy, that’s a myth USyd wants to test home-grown cannabis in the ACT Incannex joins the big leagues S&P/ASX300 index   It turns out that the lazy stoner stereotype is actually a myth,...

Neurotech International has made key appointments and changes to its board as it focuses on its developing and commercialising neurological solutions, including a cannabis breakthrough for paediatric autism. Biopharmaceutical Neurotech Int...

It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The last day for companies to submit reports is the last business day of the first month after the prior quarter. If they don’t, they...

The recent trial results success could pave the way to test other neurological illnesses, as well as an FDA approval Neurotech International (ASX:NTI) has recently announced ground-breaking results with respect to the safety, tolerability,...

Neurotech International (NTI) reports 93 per cent of patients showed symptom improvements in a recent trial of its NTI64 drug designed to treat children with ASD Under the trial, 14 patients aged eight to 17 received varying doses of NTI16...

MGC Pharma to go Phase 2 on COVID-19 in South Africa Neurotech says cannabis strain works well in children with Autism Spectrum Disorder Nova Eye’s revenue impacted by China lockdowns MGC Pharma set to start Phase IIb trial in South Afric...

Neurotech has released promising results from a world first study of a medicinal cannabis product in children which could prove to be a game-changer in autism treatment. Neurotech International (ASX:NTI) has released promising results from...

The ASX 200 and XEC small cap indices rise Attention turns to Tuesday’s date with RBA destiny Celsius Resources is hot   The ASX 200 and the Emerging Markets (XEC) indices are both trading higher on Monday up about 1.2%, ahead of tomorrow...

A medical dilemma in its own right – the modern treatment of the condition commonly known as ‘autism’ can come at a high cost and with debilitating side effects – something ASX-listed  Neurotech International aims to change. Developing a r...

A Thai university says adding cannabis to chicken feed has positive results on meat and egg quality Aussie cannabis campaigner now a Member of the Order of Australia MGC Pharma’s CBD treatment proves effective against brain tumors   Chian...

Neurotech International (ASX:NTI) has reported positive preclinical research demonstrating that its NTI164 can improve diclofenac efficacy at low doses.

Neurotech International’s (NTI) preclinical research demonstrates its proprietary cannabis strain can improve Diclofenac efficacy at low doses When combined with Neurotech’s NTI164, Diclofenac showed a 93 per cent reduction in the expressi...

Neurotech says its cannabis strain NTI164 demonstrates strong results when combined with Diclofenac Memphasys prepares for a pre-submission meeting with the US FDA for its sperm separation tech, the Felix System Neurotech reports positive...

ShareCafeWebinar Recap – NTI, MHK, RPM & ESK Catch up on the full webinar with presentations from Neurotech International (ASX: NTI), Metal Hawk (ASX: MHK), RPM Automotive Group (ASX: RPM) & Etherstack (ASX: ESK) Webinar Recap – NT...

ShareCafeNeurotech International (ASX: NTI) – Webinar Presentation Dr. Alexandra Andrews – CEO – Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inf...

Actor Woody Harrelson has opened a cannabis store in West Hollywood Releaf has plans for a weed wellness retreat in Byron Bay Incannex wants to buy out APIRx   It’s not surprising that Woody Harrelson loves weed – the actor was actually...

Kiwi medical device company TruScreen (ASX:TRU) surged 15% this morning after releasing the results of its successful clinical trial in China. The study was conducted alongside the Chinese Obstetricians and Gynaecologists Association (COGA)...

V-Con is Stockhead’s investing focused video conference series, bringing you expert insights, panel discussions and presentations from leading analysts, listed small caps and industry players. Global cannabis sales could hit $35 billion in...

Neurotech International (NTI) appoints Alexandra Andrews as Chief Executive Officer (CEO), effective from Tuesday, next week Dr Andrews has experience in corporate development, investor engagement, product development and commercialisation...

The ASX 200 Health Index (XHJ) is trading lower by 0.30% at the time of writing, compared to the broader index which is up by 0.90%. Regenerative medicine company, Avita Medical (ASX:AVH), has been awarded a purchasing contract from Premier...

Neurotech International (ASX:NTI) says preclinical studies demonstrate that NTI164 can improve the efficacy of prednisone at low doses.

The ASX 200 was unable to break free from its recent shackles, edging lower by 0.11% in the Wednesday session. But as a measure of a little more risk-on sentiment creeping back into markets, the microcap Emerging Markets index comfortably o...

Minerals260 (ASX:MI6), a spinoff from Liontown Resources (ASX:LTR), enjoyed a positive debut despite the ASX finishing down again. The ASX 200 retreated 0.26% to close at 7,821 points with all sectors in the red except consumer staples and...

ShareCafeHidden Gems Webinar Recap – NAOS Asset Management, MMM, NTI & ACW Catch up on the full webinar with a keynote presentation from NAOS Asset Management & presentations from Marley Spoon (ASX: MMM), Neurotech (ASX: NTI) &amp...

Results demonstrated the ability of Neurotech’s NTI/Dolce strains to suppress COX-2 – the main enzyme that causes inflammation in multiple sclerosis patients. Clinical-stage medicinal cannabis company Neurotech International (ASX:NTI) conti...

The results give NTI further momentum as it pursues an expanded development pathway for its proprietary medicinal cannabis treatment. Medical company Neurotech International (ASX:NTI) has announced an important new update in the development...

Neurotech International Limited (ASX:NTI) has announced the continuation of its pre-clinical program in neuro-inflammatory disease models in-line with its research and development pathway. Initial in vitro studies were carried out in collab...

Neurotech International (ASX:NTI) has announced that Professor Allan Cripps AO has been appointed as a non-executive director.

The federal government’s “patent box” initiative caught the eye of Australia’s biotech sector in Tuesday night’s Budget. Speaking with Stockhead, a number of ASX biotechs were broadly positive about the announcement. However, some industry...

Neurotech International (ASX:NTI) has announced the commencement of a phase 1/2 open-label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder.

Summary Neurotech International has commenced Phase I/II open-label clinical trial in children having Autism Spectrum Disorder. Multinational pharmaceutical company AFT Pharmaceuticals disclosed the extension of licensing of Maxigesic®...

Neurotech International Limited (ASX:NTI) has commenced a Phase I/II open label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder (ASD). This much-anticipated study is being conducted under the guidance and...

The company’s preparations over the last quarter means that it is now ready to conduct Phase I and II studies on its medicinal cannabis for autistic children. Neurotech International (ASX:NTI) has released an update on its quarterly activit...

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

ASX pot stocks have run hot in recent months but eight in particular have been particularly rewarding for shareholders. Many pot stocks ran cold prior to COVID-19 as regulatory progress stalled and global markets didn’t take off. Australia...

Australia’s medical marijuana industry is showing strong growth, according to an industry-leading biannual report. The Freshleaf Analytics report, released this morning, says that patient numbers have grown 15-fold over the past two and a h...